22 Results

People

  1. Hamlin
    Hamlin
  2. Horwitz
    Horwitz
  3. Noy
    Noy
  4. Palomba
    Palomba
  5. Zelenetz
    Zelenetz
  6. Intlekofer
    Intlekofer
  7. Kumar
    Kumar
  8. Moskowitz
    Moskowitz
  9. Caron
    Caron
  10. Vardhana
    Vardhana

Groups

  1. Center for Hematologic Malignancies (22)
  2. Department of Medicine (22)
  3. GSK Faculty (22)
  4. Hematologic Malignancies Research (22)
  5. Hematologic Malignancies, Division of (22)
  6. Lymphoma (22)
  7. Population Sciences Research Program (22)
  8. Sloan Kettering Institute Postdocs (22)
  9. Human Oncology and Pathogenesis Program (21)
  10. Survivorship Research (16)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Maria Palomba"
  4. "Andrew Zelenetz"
  5. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (22)
  2. Department of Medicine (22)
  3. GSK Faculty (22)
  4. Hematologic Malignancies Research (22)
  5. Hematologic Malignancies, Division of (22)
  6. Lymphoma (22)

More Groups

People
  1. Andrew Zelenetz (22)
  2. Ariela Noy (22)
  3. Maria Palomba (22)
  4. Paul Hamlin (22)
  5. Steven Horwitz (22)
  6. Alison Moskowitz (21)

More People

Years
  1. 2023 (9)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (16)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (2)
  4. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (16)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (1)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Journal Article

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save